Copyright
©The Author(s) 2023.
World J Clin Cases. Jan 6, 2023; 11(1): 30-46
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.30
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.30
Table 1 Differences in the clinicopathological features of type 1 and type 2 autoimmune pancreatitis
| Type 1 AIP | Type 2 AIP | |
| Histopathological pattern | LPSP | IDCP |
| Most common symptom | Obstructive jaundice | Acute pancreatitis |
| Overall prevalence of DM | 44% | 11% |
| IgG4-related disease | Yes | No |
| Epidemiology | Asia > USA, Europe | Europe, USA > Asia |
| Sex | M > F | M = F |
| Age predominance | > 50 | 30-40 |
| Serum IgG4 level | Elevated, esp. twice the upper limit of the standard (> 280 mg/dL) | Mostly normal |
| Tissue IgG4 stain | > 10 cells/HPF | < 10 cells/HPF |
| Histological features | Periductal lymphoplasmacytic infiltrate, Storiform fibrosis, Obliterative phlebitis | Granulocytic epithelial lesions |
| Other organ involvement | Yes | No |
| Associated with IBD | Rare | Common |
| Steroid response | Excellent | Excellent |
| Recurrence | Common > 30 % | Rare < 10 % |
- Citation: Kim SH, Lee YC, Chon HK. Challenges for clinicians treating autoimmune pancreatitis: Current perspectives. World J Clin Cases 2023; 11(1): 30-46
- URL: https://www.wjgnet.com/2307-8960/full/v11/i1/30.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i1.30
